A new study to understand why viral particles tend to accumulate in a specific location around a cell’s nucleus in the first several hours after viral infection has shown this phenomenon to be a novel defense mechanism used by cells to block nuclear entry and limit the infection. The implications of this sequestration of virions for use in new drug discovery and therapeutic gene delivery are discussed in an article in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free for download on the Human Gene Therapy website until May 20, 2016.
Jude Samulski, Ping-Jie Xiao, Angela Mitchell, Lu Huang, and Chengwen Li, University of North Carolina at Chapel Hill, used the chemotherapy drug Nocodazole to disrupt microtubule formation in cells and study how it would affect the previously observed accumulation of recombinant adeno-associated virus (rAAV) at the microtubule-organization center located near the nucleus. The researchers describe the fluorescence imaging technology that allowed them to analyze viral trafficking over time. They also propose how understanding this cellular defense mechanism could lead to improved strategies for rAAV-based gene therapy in the article entitled “Disruption of Microtubules Post-Virus Entry Enhances Adeno-Associated Virus Vector Transduction.”
“rAAV has become one of the most important vector systems for human gene therapy. Understanding the mechanisms by which it delivers genes to the nucleus is critical to op-timizing its performance,” says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.